An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma

Cazzola, Mario; Rogliani, Paola; Naviglio, Silvio; Calzetta, Luigino; Matera, Maria Gabriella

doi:10.1080/14656566.2022.2083955

Cited by 5 publications

(3 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also observed in the study that majority of the patients' spirometry tests to determine the asthma control were not conducted by the physicians or respirologists as recommended by the guidelines which are in line to the other studies conducted in different places or countries. [9,21,22] The reason for not using these tests would be the inaccessibility of the required equipment and technical aid. [23,24] The problem can be resolved by increasing the availability of pulmonary function tests, educating physicians and their personnel about the usefulness and importance of these tests and to provide physicians trainings regarding their use.…”

Section: Discussionmentioning

confidence: 99%

“…[8] Pharmacotherapy for asthma includes Bronchodilators (Short-acting betaagonists (SABA), Long-Acting Beta-Agonists (LABA), Antimuscarinics), Antiinflammatory drugs (Corticosteroids (oral, inhaled), Leukotriene modifiers, Monoclonal antibodies), Combination therapy (Inhaled corticosteroids with LABA) and other medications such as Theophylline and Cromones. [9] According to the Global Initiative for Asthma (GINA) classification, patients with mild asthma can effectively manage their symptoms with the use of a reliever medication as needed or a low-dose Inhaled Corticosteroid (ICS) inhaler. For individuals with moderate asthma, the use of a low-dose ICS combined with a long-acting beta 2 agonist (LABA) can effectively control symptoms.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Treatment on Asthma Control in Quetta Pakistan

Sehar¹,

Haq²,

Tahir³

et al. 2023

J. Pharm. Practice and Community Med.

View full text Add to dashboard Cite

Background: Poorly controlled asthma may lead to decreased lung function, increase the risk of complications and more episodes of exacerbations, increased healthcare utilization, including more frequent hospitalizations and emergency room visits. Regular monitoring of asthma symptoms and lung function can help identify any potential issues in asthma control and ensure optimal management. Objectives:The study aims to assess the asthma control by the usage of asthma controller medications especially, corticosteroids, bronchodilators and leukotriene modifiers, among patients receiving treatment through well-validated questionnaire. Materials and Methods: A cross-sectional study with a sample of 361 was conducted in different public hospitals outpatient departments and clinics of Quetta Pakistan by using a convenience sampling technique. The Asthma Control Questionnaire (ACQ) was used to measure the asthma control of the asthmatic patients. The descriptive and inferential statistics have been done by using SPSS version 20 with a p value <0.05. Results: The study found that an average score of asthma control was 3.1±1.10 thereby indicating uncontrolled asthma with also 62.3% of study participants had uncontrolled asthma, no patient had controlled asthma. An increased number of medications including the use of corticosteroids and leukotriene modifiers posed an impact on asthma control of the study population. Conclusion:The study concluded that corticosteroids and leukotriene modifiers can be effective in asthma control and it is suggested for the future studies that route of administration and treatment guidelines must also be determined along with the asthma control to gain a complete picture of impact of treatment and management on any health outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of Treatment on Asthma Control in Quetta Pakistan

Sehar¹,

Haq²,

Tahir³

et al. 2023

J. Pharm. Practice and Community Med.

View full text Add to dashboard Cite

show abstract

“…In recent years, a lot of effort has been put into the development of a more personalised approach [ 13 ]. The ability to target specific inflammatory mediators and cellular pathways via highly selective therapeutic agents has progressively revolutionised the treatment of a complex, heterogeneous disorder such as asthma [ 14 ]. Although current medications may improve symptom control, QoL, and the frequency and severity of exacerbations, they do not really induce asthma remission [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Inhaled corticosteroids (ICS) remain the mainstay of asthma treatment, along with bronchodilators serving as control agents in combination with ICS or reliever therapy. Although current pharmacological treatments improve symptom control, health status, and the frequency and severity of exacerbations, they do not really change the natural course of asthma, including disease remission. Considering the highly heterogeneous nature of asthma, there is a strong need for innovative medications that selectively target components of the inflammatory cascade. The aim of this review was to systematically assess current investigational agents in Phase I and II randomised controlled trials (RCTs) over the last five years. Sixteen classes of novel therapeutic options were identified from 19 RCTs. Drugs belonging to different classes, such as the anti-interleukin (IL)-4Rα inhibitors, anti-IL-5 monoclonal antibodies (mAbs), anti-IL-17A mAbs, anti-thymic stromal lymphopoietin (TSLP) mAbs, epithelial sodium channel (ENaC) inhibitors, bifunctional M3 receptor muscarinic antagonists/β2-adrenoceptor agonists (MABAs), and anti-Fel d 1 mAbs, were found to be effective in the treatment of asthma, with lung function being the main assessed outcome across the RCTs. Several novel investigational molecules, particularly biologics, seem promising as future disease-modifying agents; nevertheless, further larger studies are required to confirm positive results from Phase I and II RCTs.

show abstract